DBP International: the feasibility studies for clinical site selection for Phase 1 SI-053 clinical trial is finalized - seven out of ten milestones for the clinical trial of SI-053 have been completed
Double Bond Pharmaceutical International AB (publ) (“DBP” or “Double Bond Pharmaceutical”) reports that the feasibility studies for clinical site selection for SI-053 Phase 1 clinical trial have been completed which resulted in the selection of four sites within the EU. This process of the feasibility studies has included: identify clinical investigators who are interested in participating in the trial, assessing site facilities, obtain input from investigators on trial design to align study procedures with clinical practice and support optimal patient recruitment, as well as to understand